Chemotherapy-free regimen results in 100% complete response rate, 85% complete molecular remission rate in newly diagnosed patients A combination of ponatinib and blinatumomab was found to be safe and highly effective in patients with newly diagnosed or relapsed/refractory Philadelphia chromosome-positive […]
